Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) have earned a consensus recommendation of “Hold” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $19.8750.
SLP has been the subject of a number of research reports. Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings upgraded Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. William Blair cut Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Craig Hallum downgraded Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price for the company. in a research report on Thursday, June 18th. Finally, TD Cowen cut their price target on Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, April 10th.
View Our Latest Stock Report on Simulations Plus
Simulations Plus Stock Performance
Simulations Plus (NASDAQ:SLP – Get Free Report) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.23 by $0.07. Simulations Plus had a net margin of 9.88% and a return on equity of 13.78%. The business had revenue of $21.89 million during the quarter, compared to the consensus estimate of $20.90 million. Equities research analysts forecast that Simulations Plus will post 0.8 earnings per share for the current year.
Insider Buying and Selling at Simulations Plus
In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the sale, the director owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. This represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,177 shares of company stock valued at $108,754 over the last ninety days. Corporate insiders own 19.10% of the company’s stock.
Hedge Funds Weigh In On Simulations Plus
Institutional investors and hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL bought a new position in Simulations Plus in the 3rd quarter worth about $1,810,000. Nicholas Company Inc. lifted its holdings in shares of Simulations Plus by 42.9% in the fourth quarter. Nicholas Company Inc. now owns 262,712 shares of the technology company’s stock worth $4,789,000 after buying an additional 78,854 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Simulations Plus by 154.7% in the third quarter. JPMorgan Chase & Co. now owns 167,646 shares of the technology company’s stock valued at $2,526,000 after acquiring an additional 101,822 shares during the period. First Light Asset Management LLC boosted its position in shares of Simulations Plus by 115.0% in the third quarter. First Light Asset Management LLC now owns 767,760 shares of the technology company’s stock valued at $11,570,000 after acquiring an additional 410,603 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Simulations Plus by 167.9% during the fourth quarter. GSA Capital Partners LLP now owns 62,322 shares of the technology company’s stock valued at $1,136,000 after acquiring an additional 39,059 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors.
About Simulations Plus
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Featured Articles
- Five stocks we like better than Simulations Plus
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
